The Future of Antisense Oligonucleotides in the Treatment of Respiratory Diseases

Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A 1978; 75(1): 280–4 Crooke ST. Vitravene: another piece in the mosaic. Antisense Nucleic Acid Drug Dev 1998; 8(4): vii–viii Pirollo KF, Rait A, Sleer LS, et al. Antisense therapeutics: from theory to clinical practice. Pharmacol Ther 2003; 99(1): 55–77 Dash P, Lotan I, Knapp M, et al. Selective elimination of mRNAs in vivo: complementary oligodeoxynucleotides promote RNA degradation by an RNase H-like activity. Proc Natl Acad Sci U S A 1987; 84(22): 7896–900 Mercatante DR, Kole R. Control of alternative splicing by antisense oligonucleotides as a potential chemotherapy: effects on gene expression. Biochim Biophys Acta 2002; 1587(2–3): 126–32 Matzura H, Eckstein F. A polyribonucleotide containing alternation P = O and P = S linkages. Eur J Biochem 1968; 3(4): 448–52 Nielsen PE, Egholm M, Berg RH, et al. Peptide nucleic acids (PNAs): potential antisense and anti-gene agents. Anticancer Drug Des 1993; 8(1): 53–63 Wahlestedt C, Salmi P, Good L, et al. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci U S A 2000; 97(10): 5633–8 Doherty EA, Doudna JA. Ribozyme structures and mechanisms. Annu Rev Biochem 2000; 69: 597–615 Braasch DA, Corey DR. Novel antisense and peptide nucleic acid strategies for controlling gene expression. Biochemistry 2002; 41(14): 4503–10 Heasman J. Morpholino oligos: making sense of antisense? Dev Biol 2002; 243(2): 209–14 Stevenson M. Therapeutic potential of RNA interference. N Engl J Med 2004; 351(17): 1772–7 Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391(6669): 806–11 Ichim TE, Li M, Qian H, et al. RNA interference: a potent tool for gene-specific therapeutics. Am J Transplant 2004;4(8): 1227–36 Caplen NJ, Mousses S. Short interfering RNA (siRNA)-mediated RNA interference (RNAi) in human cells. Ann N Y Acad Sci 2003; 1002: 56–62 Morris KV, Chan SW, Jacobsen SE, et al. Small interfering RNA-induced transcriptional gene silencing in human cells. Science 2004; 305(5688): 1289–92 Miller VM, Xia H, Marrs GL, et al. Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci U S A 2003; 100(12): 7195–200 Ding H, Schwarz DS, Keene A, et al. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis. Aging Cell 2003; 2(4): 209–17 Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 2004; 431(7006): 371–8 Scacheri PC, Rozenblatt-Rosen O, Caplen NJ, et al. Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci U S A 2004; 101(7): 1892–7 Zhang W, Yang H, Kong X, et al. Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med 2005; 11(1): 56–62 Bitko V, Musiyenko A, Shulyayeva O, et al. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005; 11(1): 50–5 Dagle JM, Weeks DL. Oligonucleotide-based strategies to reduce gene expression. Differentiation 2001; 69(2-3): 75–82 Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709–60 Bennett CF, Chiang MY, Chan H, et al. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 1992; 41(6): 1023–33 Capaccioli S, Di Pasquale G, Mini E, et al. Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum. Biochem Biophys Res Commun 1993; 197(2): 818–25 Zelphati O, Szoka Jr FC. Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Pharm Res 1996; 13(9): 1367–72 Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54(4): 987–92 Freimark BD, Blezinger HP, Florack VJ, et al. Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: cationic lipid complexes. J Immunol 1998; 160(9): 4580–6 Dow SW, Fradkin LG, Liggitt DH, et al. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol 1999; 163(3): 1552–61 Chien PY, Wang J, Carbonaro D, et al. Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo. Cancer Gene Ther 2005; 12(3): 321–8 Wiseman JW, Goddard CA, McLelland D, et al. A comparison of linear and branched polyethylenimine (PEI) with DCChol/DOPE liposomes for gene delivery to epithelial cells in vitro and in vivo. Gene Ther 2003; 10(19): 1654–62 Chollet P, Favrot MC, Hurbin A, et al. Side-effects of a systemic injection of linear polyethylenimine-DNA complexes. J Gene Med 2002; 4(1): 84–91 Kumar M, Behera AK, Lockey RF, et al. Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum Gene Ther 2002; 13(12): 1415–25 Ravi Kumar MN, Bakowsky U, Lehr CM. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials 2004; 25(10): 1771–7 Mohapatra SS. Mucosal gene expression vaccine: a novel vaccine strategy for respiratory syncytial virus. Pediatr Infect Dis J 2003; 22(2 Suppl.): S100–3 Leong KW, Mao HQ, Truong L, et al. DNA-polycation nanospheres as non-viral gene delivery vehicles. J Control Release 1998; 53(1–3): 183–93 Haitsma JJ, Lachmann U, Lachmann B. Exogenous surfactant as a drug delivery agent. Adv Drug Deliv Rev 2001; 47(2–3): 197–207 Nyce JW, Metzger WJ. DNA antisense therapy for asthma in an animal model. Nature 1997; 385(6618): 721–5 Finotto S, Buerke M, Lingnau K, et al. Local administration of antisense phosphorothioate oligonucleotides to the c-kit ligand, stem cell factor, suppresses airway inflammation and IL-4 production in a murine model of asthma. J Allergy Clin Immunol 2001; 107(2): 279–86 Finotto S, De Sanctis GT, Lehr HA, et al. Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. J Exp Med 2001; 193(11): 1247–60 Allakhverdi Z, Allam M, Renzi PM. Inhibition of antigen-induced eosinophilia and airway hyperresponsiveness by antisense oligonucleotides directed against the common beta chain of IL-3, IL-5, GM-CSF receptors in a rat model of allergic asthma. Am J Respir Crit Care Med 2002; 165(7): 1015–21 Massaro D, Massaro GD, Clerch LB. Noninvasive delivery of small inhibitory RNA and other reagents to pulmonary alveoli in mice. Am J Physiol Lung Cell Mol Physiol 2004; 287(5): L1066–70 Levin AA. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1999; 1489(1): 69–84 Crooke ST. Progress in antisense technology. Annu Rev Med 2004; 55: 61–95 Tanaka M, Nyce JW. Respirable antisense oligonucleotides: a new drug class for respiratory disease. Respir Res 2001; 2(1): 5–9 Stenton GR, Ulanova M, Dery RE, et al. Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase. J Immunol 2002; 169(2): 1028–36 Stein CA. Is irrelevant cleavage the price of antisense efficacy? Pharmacol Ther 2000; 85(3): 231–6 Guvakova MA, Yakubov LA, Vlodavsky I, et al. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem 1995; 270(6): 2620–7 Fennewald SM, Rando RF. Inhibition of high affinity basic fibroblast growth factor binding by oligonucleotides. J Biol Chem 1995; 270(37): 21718–21 Cotter FE. Antisense oligonucleotides for haematological malignancies. Haematologica 1999; 84Suppl EHA-4: 19–22 Sereni D, Tubiana R, Lascoux C, et al. Pharmacokinetics and tolerability of intravenous trecovirsen (GEM 91), an antisense phosphorothioate oligonucleotide, in HIV-positive subjects. J Clin Pharmacol 1999; 39(1): 47–54 Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004; 4(4): 249–58 Agrawal S, Kandimalla ER. Role of Toll-like receptors in antisense and siRNA. Nat Biotechnol 2004; 22(12): 1533–7 Bjorck T, Gustafsson LE, Dahlen SE. Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine. Am Rev Respir Dis 1992; 145(5): 1087–91 Ali S, Mustafa SJ, Metzger WJ. Adenosine-induced bronchoconstriction and contraction of airway smooth muscle from allergic rabbits with late-phase airway obstruction: evidence for an inducible adenosine Al receptor. J Pharmacol Exp Ther 1994; 268(3): 1328–34 Maus U, Rosseau S, Mandrakas N, et al. Cationic lipids employed for antisense oligodeoxynucleotide transport may inhibit vascular cell adhesion molecule-1 expression in human endothelial cells: a word of caution. Antisense Nucleic Acid Drug Dev 1999; 1: 71–80 Lysik MA, Wu-Pong S. Innovations in oligonucleotide drug delivery. J Pharm Sci 2003; 92(8): 1559–73 Darby C, Geahlen RL, Schreiber AD. Stimulation of macrophage Fc gamma RIIIA activates the receptor-associated protein tyrosine kinase Syk and induces phosphorylation of multiple proteins including p95Vav and p62/GAP-associated protein. J Immunol 1994; 152(11): 5429–37 Costello PS, Turner M, Walters AE, et al. Critical role for the tyrosine kinase Syk in signalling through the high affinity IgE receptor of mast cells. Oncogene 1996; 13(12): 2595–605 Kiefer F, Brumell J, Al-Alawi N, et al. The Syk protein tyrosine kinase is essential for Fc gamma receptor signaling in macrophages and neutrophils. Mol Cell Biol 1998; 18(7): 4209–20 Matsuda M, Park JG, Wang DC, et al. Abrogation of the Fc gamma receptor IIA-mediated phagocytic signal by stem-loop Syk antisense oligonucleotides. Mol Biol Cell 1996; 7(7): 1095–106 Stenton GR, Kim MK, Nohara O, et al. Aerosolized Syk antisense suppresses Syk expression, mediator release from macrophages, and pulmonary inflammation. J Immunol 2000; 164(7): 3790–7 Coopman PJ, Do MT, Barth M, et al. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature 2000; 406(6797): 742–7 Moroni M, Soldatenkov V, Zhang L, et al. Progressive loss of Syk and abnormal proliferation in breast cancer cells. Cancer Res 2004; 64(20): 7346–54 Wang S, Ding YB, Chen GY, et al. Hypermethylation of Syk gene in promoter region associated with oncogenesis and metastasis of gastric carcinoma. World J Gastroenterol 2004; 10(12): 1815–8 Ulanova M, Puttagunta L, Marcet-Palacios M, et al. Syk tyrosine kinase participates in β1 integrin signaling and inflammatory responses in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2005; 288(3): L297–507 Lowell CA. Src-family kinases: rheostats of immune cell signaling. Mol Immunol 2004; 41(6–7): 631–43 Jouvin MH, Adamczewski M, Numerof R, et al. Differential control of the tyrosine kinases Lyn and Syk by the two signaling chains of the high affinity immunoglobulin E receptor. J Biol Chem 1994; 269(8): 5918–25 Lin S, Cicala C, Scharenberg AM, et al. The FcεRI β subunit functions as an amplifier of FcεRI γ-mediated cell activation signals. Cell 1996; 85(7): 985–95 Stafford S, Lowell C, Sur S, et al. Lyn tyrosine kinase is important for IL-5-stimulated eosinophil differentiation. J Immunol 2002; 168(4): 1978–83 Duan W, Chan JH, McKay K, et al. Inhaled p38α mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am J Respir Crit Care Med 2004; 171(6): 571–8 Wulczyn FG, Krappmann D, Scheidereit C. The NF-kappa B/Rel and I kappa B gene families: mediators of immune response and inflammation. J Mol Med 1996; 74(12): 749–69 Choi IW, Kim DK, Ko HM, et al. Administration of antisense phosphorothioate oligonucleotide to the p65 subunit of NF-kappaB inhibits established asthmatic reaction in mice. Int Immunopharmacol 2004; 4(14): 1817–28 Karras JG, McGraw K, McKay RA, et al. Inhibition of antigen-induced eosinophilia and late phase airway hyperresponsiveness by an IL-5 antisense oligonucleotide in mouse models of asthma. J Immunol 2000; 164(10): 5409–15 Zsebo KM, Williams DA, Geissler EN, et al. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 1990; 63(1): 213–24 Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997; 89(4): 587–96 Quarcoo D, Weixler S, Groneberg D, et al. Inhibition of signal transducer and activator of transcription 1 attenuates allergen-induced airway inflammation and hyperreactivity. J Allergy Clin Immunol 2004; 114(2): 288–95 Popescu FD. New asthma drugs acting on gene expression. J Cell Mol Med 2003; 7(4): 475–86 Komiya T, Tanigawa Y, Hirohashi S. Cloning and identification of the gene gob-5, which is expressed in intestinal goblet cells in mice. Biochem Biophys Res Commun 1999; 255(2): 347–51 Nakanishi A, Morita S, Iwashita H, et al. Role of gob-5 in mucus overproduction and airway hyperresponsiveness in asthma. Proc Natl Acad Sci U S A 2001; 98(9): 5175–80 Sime PJ, Xing Z, Graham FL, et al. Adenovector-mediated gene transfer of active transforming growth factor-betal induces prolonged severe fibrosis in rat lung. J Clin Invest 1997; 100(4): 768–76 Xing Z, Braciak T, Ohkawara Y, et al. Gene transfer for cytokine functional studies in the lung: the multifunctional role of GM-CSF in pulmonary inflammation. J Leukoc Biol 1996; 59(4): 481–8 Knowles MR, Hohneker KW, Zhou Z, et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 1995; 333(13): 823–31 Dreyfus DH, Matczuk A, Fuleihan R. An RNA external guide sequence ribozyme targeting human interleukin-4 receptor alpha mRNA. Int Immunopharmacol 2004; 4(8): 1015–27 Plehn-Dujowich D, Altman S. Effective inhibition of influenza virus production in cultured cells by external guide sequences and ribonuclease P. Proc Natl Acad Sci U S A 1998; 95(13): 7327–32 Rippmann JF, Schnapp A, Weith A, et al. Gene silencing with STAT6 specific siRNAs blocks eotaxin release in IL-4/TNFalpha stimulated human epithelial cells. FEBS Lett 2005; 579(1): 173–8 Allen M, Heinzmann A, Noguchi E, et al. Positional cloning of a novel gene influencing asthma from chromosome 2ql4. Nat Genet 2003; 35(3): 258–63 Van Eerdewegh P, Little RD, Dupuis J, et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature 2002; 418(6896): 426–30 Laitinen T, Polvi A, Rydman P, et al. Characterization of a common susceptibility locus for asthma-related traits. Science 2004; 304(5668): 300–4 Stahel RA, Zangemeister-Wittke U. Antisense oligonucleotides for cancer therapy: an overview. Lung Cancer 2003; 41Suppl. 1: S81–8 Ziegler A, Luedke GH, Fabbro D, et al. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 1997; 89(14): 1027–36 Zangemeister-Wittke U, Leech SH, Olie RA, et al. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res 2000; 6(6): 2547–55 Kim R, Emi M, Tanabe K, et al. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy. Cancer 2004; 101(11): 2491–502 Herbst RS, Frankel SR. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer. Clin Cancer Res 2004; 10 (12 Pt 2): 4245s–8s Villalona-Calero MA, Ritch P, Figueroa JA, et al. A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004; 10 (18 Pt 1): 6086–93 Wang H, Cai Q, Zeng X, et al. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RI alpha subunit of protein kinase A after oral administration. Proc Natl Acad Sci U S A 1999; 96(24): 13989–94 Coudert B, Anthoney A, Fiedler W, et al. Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer: a European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report. Eur J Cancer 2001; 37(17): 2194–8 Jansen B, Zangemeister-Wittke U. Antisense therapy for cancer: the time of truth. Lancet Oncol 2002; 3(11): 672–83 Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3(8): 917–21 Olie RA, Simoes-Wust AP, Baumann B, et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000; 60(11): 2805–9 Suzuki C, Daigo Y, Kikuchi T, et al. Identification of COX17 as a therapeutic target for non-small cell lung cancer. Cancer Res 2003; 63(21): 7038–41 Sak A, Wurm R, Elo B, et al. Increased radiation-induced apoptosis and altered cell cycle progression of human lung cancer cell lines by antisense oligodeox-ynucleotides targeting p53 and p21 (WAF1/CIP1). Cancer Gene Ther 2003; 10(12): 926–34 Raben D, Helfrich B. Angiogenesis inhibitors: a rational strategy for radiosensitization in the treatment of non-small-cell lung cancer? Clin Lung Cancer 2004; 6(1): 48–57 Pold M, Krysan K, Pold A, et al. Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small-cell lung cancer. Cancer Res 2004; 64(18): 6549–55 Kuhn H, Kopff C, Konrad J, et al. Influence of basic fibroblast growth factor on the proliferation of non-small cell lung cancer cell lines. Lung Cancer 2004; 44(2): 167–74 Stabile LP, Lyker JS, Huang L, et al. Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy. Gene Ther 2004; 11(3): 325–35 Hopkins-Donaldson S, Cathomas R, Simoes-Wust AP, et al. Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment. Int J Cancer 2003; 106(2): 160–6 Yin JQ, Gao J, Shao R, et al. siRNA agents inhibit oncogene expression and attenuate human tumor cell growth. J Exp Ther Oncol 2003; 3(4): 194–204 Sumimoto H, Yamagata S, Shimizu A, et al. Gene therapy for human small-cell lung carcinoma by inactivation of Skp-2 with virally mediated RNA interference. Gene Ther 2005; 12(1): 95–100 Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, et al. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 2002; 94(24): 1863–77 Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296(5567): 550–3 Martinez LA, Naguibneva I, Lehrmann H, et al. Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci U S A 2002; 99(23): 14849–54 Nieth C, Priebsch A, Stege A, et al. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett 2003; 545(2–3): 144–50 Maggon K, Barik S. New drugs and treatment for respiratory syncytial virus. Rev Med Virol 2004; 14(3): 149–68 Xu Z, Kuang M, Okicki JR, et al. Potent inhibition of respiratory syncytial virus by combination treatment with 2–5A antisense and ribavirin. Antiviral Res 2004; 61(3): 195–206 Wu CJ, Huang HW, Liu CY, et al. Inhibition of SARS-CoV replication by siRNA. Antiviral Res 2005; 65(1): 45–8